HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on Elicio Therapeutics (NASDAQ:ELTX) and increased the price target from $10 to $11. This adjustment reflects a positive outlook on the company's stock.
January 17, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics' stock may see a positive short term impact due to the maintained Buy rating and raised price target from $10 to $11 by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors. The increase in price target by HC Wainwright & Co. suggests a strong belief in the potential growth of Elicio Therapeutics, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100